B. Metzler seel. Sohn & Co. AG Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO

B. Metzler seel. Sohn & Co. AG acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,506 shares of the company's stock, valued at approximately $1,304,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BBIO. First Bank & Trust grew its stake in shares of BridgeBio Pharma by 1.6% in the second quarter. First Bank & Trust now owns 8,797 shares of the company's stock worth $655,000 after acquiring an additional 142 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of BridgeBio Pharma by 13.8% in the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company's stock worth $123,000 after buying an additional 199 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of BridgeBio Pharma by 4.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock worth $396,000 after buying an additional 244 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after buying an additional 245 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of BridgeBio Pharma by 0.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company's stock valued at $3,970,000 after buying an additional 246 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.

Analyst Ratings Changes

BBIO has been the topic of several analyst reports. Morgan Stanley lowered their price objective on BridgeBio Pharma from $98.00 to $97.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Wells Fargo & Company upped their price target on BridgeBio Pharma from $98.00 to $102.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Piper Sandler upped their target price on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the company an "overweight" rating in a research note on Tuesday, August 11th. Finally, Raymond James Financial downgraded shares of BridgeBio Pharma from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 26th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $100.79.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock opened at $81.50 on Monday. The company's fifty day simple moving average is $78.85 and its 200-day simple moving average is $73.29. The stock has a market capitalization of $15.93 billion, a PE ratio of -22.83 and a beta of 0.96. BridgeBio Pharma, Inc. has a 1-year low of $46.81 and a 1-year high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analysts' expectations of $220.91 million. BridgeBio Pharma's quarterly revenue was up 120.4% compared to the same quarter last year. During the same period last year, the business earned ($0.95) EPS. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.62 EPS for the current year.

Insider Transactions at BridgeBio Pharma

In other news, Director Jennifer E. Cook sold 148,589 shares of the firm's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the sale, the director directly owned 8,383 shares in the company, valued at $742,230.82. This trade represents a 94.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of BridgeBio Pharma stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the transaction, the director owned 22,579 shares in the company, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 387,343 shares of company stock valued at $30,289,400. Company insiders own 14.23% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source